Project Grant R21CA292205
Award Date
7/15/25
Completion Date
6/30/27
Dollars Obligated
$395K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cold Spring Harbor Laboratory provides $640,583 to enhance the efficacy of immunotherapy against metastatic colorectal cancer. The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their metabolic fitness and anti-tumor activity within the tumor microenvironment. The research aims to delineate the mechanisms by which PPARD activation improves CD8+ T cell...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop a novel nanocarrier-based immunochemotherapy for the treatment of metastatic colorectal cancer (mCRC). The key products and services to be delivered include: Developing and characterizing a nanoparticle carrier capable of co-delivering small interfering RNA targeting the IRHOM1 protein and a prodrug conjugate of...
This federal Project Grant award of $221,456.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop and optimize a novel approach for enriching microbes from clinical cancer samples to enable deep metaproteomic analysis. The research team, led by the Regents of the University of Minnesota, will pursue two specific aims: 1) Optimize and evaluate the CS-BONCAT (bio-orthogonal non-canonical amino acid tagging) method in samples of known...
This Project Grant award of $352,275.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to develop a novel agent called MITOMET to target mitochondria in lung cancer cells with co-occurring KRAS and LKB1 mutations. The 5-year project, which began on January 1, 2025, seeks to assess the safety and efficacy of MITOMET in suppressing the malignant progression of lung tumors, determine its ability to modulate the tumor immune microenvironment, and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $406,611.00 to the University of Texas Health Science Center at Houston to investigate the role and therapeutic targeting of the GPR56 protein in colorectal cancer. The key objectives are to: Characterize the role and signaling mechanisms of GPR56 in colorectal cancer stem cells and metastasis using patient-derived organoids. Develop and evaluate highly potent GPR56-targeted...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700.00 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at overcoming rapid resistance to targeted therapies in colorectal cancer. The key products and services to be delivered under this 2-year award include: Evaluating how intrinsic tumor features modulate the development of resistance to targeted therapies in colorectal cancer through analysis of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,618,500.00 to the Regents of the University of Minnesota to support research aimed at "Targeting eIF4F Complex-Driven Translation of Oncogenic mRNAs in CRPC". The 3-year award, which runs from June 1, 2025 to May 31, 2028, will fund advanced biomedical research focused on innovative solutions to transform healthcare for military service...
This federal Project Grant award, valued at $849,371.00, was issued on August 2, 2024 by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports research aimed at "Hijacking Post-Translational Arginylation for Targeted Protein Degradation" at the Washington University in St. Louis. The key research activities include: Applying computational techniques to identify potential ATE1 binder hits for targeted protein degradation....
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $105,189 to the Regents of the University of Minnesota to advance research on inhibiting the structural dynamics of the APOBEC3A (A3A) and APOBEC3B (A3B) enzymes. The key objectives are to: Elucidate the structures of A3A and A3B when bound to viral inhibitors, such as ribonucleotide reductases from Macacine G-herpesvirus 11 and Kaposi Sarcoma-associated Herpesvirus, using...